감염 감시 솔루션 시장 : 구성요소, 기술, 감시 대상 감염증 유형, 도입 형태, 용도, 최종 사용자별 예측(2026-2032년)

The Infection Surveillance Solution Market is projected to grow by USD 2,442.92 million at a CAGR of 14.00% by 2032.

Infection surveillance solutions are becoming core infrastructure for hospitals, laboratories, long-term care facilities, and public health agencies as healthcare systems respond to healthcare-associated infections, antimicrobial resistance, and emerging pathogens. The WHO reports that 7 in 100 patients in high-income countries and 15 in 100 patients in low- and middle-income countries acquire at least one healthcare-associated infection during acute care, while the CDC estimates that about 1 in 31 U.S. hospital patients has at least one healthcare-associated infection on any given day.

Modern infection surveillance platforms integrate electronic health records, laboratory information systems, pharmacy data, admission-discharge-transfer feeds, microbiology results, and case reporting workflows to accelerate detection, investigation, and prevention. Demand is rising for automated infection prevention software, real-time outbreak monitoring, antimicrobial stewardship analytics, and interoperable reporting tools that reduce manual chart review, improve regulatory readiness, and strengthen patient safety programs.

Transformative Shifts in the Infection Surveillance Landscape

The infection surveillance landscape is shifting from retrospective compliance reporting to continuous, data-driven prevention. Healthcare organizations are replacing spreadsheet-based infection tracking with automated surveillance engines that identify clusters, flag multidrug-resistant organisms, monitor device-associated infections, and support timely interventions across inpatient, outpatient, and community settings.

Regulatory pressure and global preparedness priorities are also reshaping adoption. CDC NHSN reporting, ECDC HAI-Net surveillance, WHO GLASS antimicrobial resistance monitoring, and national digital health programs are encouraging standardized definitions, interoperable data exchange, and auditable infection prevention workflows. At the same time, cloud deployment, API-based integration, data quality management, and cybersecurity-by-design are becoming essential buying criteria for healthcare IT leaders.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is expanding the value of infection surveillance by improving early signal detection, risk stratification, and workload prioritization. Machine learning models can analyze microbiology results, antibiotic orders, device utilization, patient movement, and clinical notes to identify patterns that may be missed during manual review. Natural language processing is increasingly used to extract infection-relevant context from unstructured clinical documentation, including progress notes, radiology narratives, and discharge summaries.

The cumulative impact of AI is strongest when algorithms are clinically validated, explainable, and embedded into infection prevention workflows. AI-enabled surveillance can support faster outbreak recognition, more targeted isolation precautions, better antimicrobial stewardship, and more consistent reporting, but implementation requires strong data governance, bias monitoring, privacy controls, cybersecurity safeguards, and human oversight to ensure patient safety and regulatory trust.

Key Regional Insights

North America remains a leading region for infection surveillance solution adoption, supported by mature EHR penetration, CDC NHSN reporting requirements, antimicrobial stewardship mandates, and strong investment in hospital quality improvement. Europe benefits from ECDC-led surveillance networks, national infection control programs, and European Union digital health interoperability priorities, with demand concentrated around standardized reporting, privacy-compliant analytics, and cross-border preparedness. Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, Australia, and ASEAN health systems invest in hospital digitization, laboratory modernization, and infectious disease preparedness.

Latin America shows growing demand in Brazil and Mexico as private hospital networks and public health agencies strengthen infection control capacity, antimicrobial resistance monitoring, and accreditation-driven quality programs. The Middle East, particularly GCC markets, is adopting advanced surveillance across smart hospitals and digitally connected health systems, with emphasis on rapid outbreak detection and centralized dashboards. Africa is prioritizing scalable, laboratory-linked surveillance to address outbreak response, antimicrobial resistance, and resource-constrained infection prevention, supported by regional public health initiatives and investments in disease monitoring infrastructure.

Key Group Insights

ASEAN countries are strengthening infection surveillance through hospital accreditation, regional disease monitoring, and investments in digital health infrastructure, with adoption shaped by varying levels of EHR maturity and laboratory connectivity. The GCC is advancing high-acuity, technology-enabled healthcare systems, making cloud-based infection prevention platforms, outbreak dashboards, and antimicrobial stewardship tools increasingly relevant for public and private hospitals. The European Union emphasizes cross-border data standards, privacy compliance, and coordinated infection monitoring, creating demand for interoperable and GDPR-aligned platforms that support national and regional reporting frameworks.

BRICS countries represent high-volume opportunities due to large patient populations, expanding hospital networks, and rising antimicrobial resistance surveillance needs across complex public and private care systems. G7 markets lead in advanced analytics, regulatory reporting, clinical validation, and integrated quality improvement, supporting adoption of automated infection surveillance software and AI-enabled decision support. NATO members increasingly view infectious disease surveillance as part of health security, resilience planning, military medical readiness, and emergency preparedness, reinforcing the need for secure, interoperable, and rapidly deployable surveillance systems.

Key Country Insights

The United States leads demand through CDC NHSN participation, quality reporting, antimicrobial stewardship requirements, and integrated hospital IT ecosystems, while Canada emphasizes provincial surveillance, patient safety, and coordinated infection prevention programs. Mexico and Brazil are strengthening hospital infection control programs as healthcare modernization, accreditation, and public health reporting needs accelerate. In Europe, the United Kingdom, Germany, France, Italy, and Spain prioritize standardized reporting, infection prevention performance, and privacy-compliant data exchange, while Russia maintains demand for infectious disease monitoring across large regional health systems and centralized public health structures.

China and India represent major growth markets due to large hospital networks, rising digital health investment, laboratory expansion, and heightened focus on antimicrobial resistance. Japan, South Korea, and Australia show strong readiness for AI-enabled surveillance due to advanced health IT adoption, aging populations, mature infection control frameworks, and established public health reporting practices. Across these countries, procurement decisions increasingly center on interoperability, clinical validation, automation, cybersecurity, regulatory alignment, and measurable reduction in infection prevention workload.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize interoperable infection surveillance platforms that connect EHR, laboratory, pharmacy, bed management, device utilization, and public health reporting systems. Solutions should support recognized definitions, configurable rules, real-time alerts, role-based dashboards, and auditable workflows that help infection prevention teams move from passive monitoring to proactive intervention.

Vendors and providers should invest in AI governance, cybersecurity, data quality, and clinical validation before scaling predictive analytics. Leaders can strengthen adoption by aligning surveillance programs with antimicrobial stewardship, quality improvement, accreditation, and emergency preparedness goals. Clear ROI measurement should include reduced manual review time, faster outbreak detection, improved reporting accuracy, better targeting of prevention resources, and stronger readiness for regulatory audits.

Research Methodology

This executive summary is based on a structured research approach combining secondary research, expert interpretation, and evidence triangulation. Sources include publicly available guidance and datasets from the WHO, CDC, ECDC, national health ministries, peer-reviewed infection prevention literature, hospital quality reporting frameworks, digital health policy documents, and antimicrobial resistance surveillance programs.

The methodology evaluates demand drivers, regulatory requirements, technology adoption, regional healthcare infrastructure, interoperability readiness, and procurement priorities. Findings are validated by comparing global health indicators, surveillance frameworks, hospital digitization trends, infection prevention standards, and public health reporting requirements across regions, groups, and key countries to ensure evidence-led insights for infection surveillance solutions.

Conclusion

Infection surveillance solutions are moving from administrative tools to strategic platforms for patient safety, antimicrobial resistance control, and health system resilience. The most effective solutions combine automation, interoperability, clinically governed AI, secure data exchange, and actionable analytics to support infection prevention teams in real time.

As healthcare systems face persistent healthcare-associated infections and recurring infectious disease threats, demand will continue to shift toward scalable, secure, and evidence-based surveillance platforms. Organizations that invest early in integrated infection prevention intelligence will be better positioned to improve outcomes, meet reporting obligations, reduce preventable risk, and strengthen preparedness.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Infection Surveillance Solution Market, by Component

• 7.1. Services
  • 7.1.1. Consulting
  • 7.1.2. Implementation & Integration
  • 7.1.3. Maintenance & Upgrades
  • 7.1.4. Training & Support
• 7.2. Software
  • 7.2.1. Alert Management
  • 7.2.2. Data Analytics
  • 7.2.3. Reporting & Visualization

8. Infection Surveillance Solution Market, by Technology

• 8.1. Artificial Intelligence And Machine Learning
  • 8.1.1. Supervised Learning
  • 8.1.2. Unsupervised Learning
• 8.2. Internet Of Things And Sensor Based
• 8.3. Traditional Rule Based

9. Infection Surveillance Solution Market, by Infection Type Monitored

• 9.1. Bloodstream Infections
• 9.2. Surgical Site Infections
• 9.3. Urinary Tract Infections
• 9.4. Gastrointestinal Infections
• 9.5. Respiratory Infections
• 9.6. Device-Associated Infections
• 9.7. Multidrug-Resistant Organism Infections

10. Infection Surveillance Solution Market, by Deployment Mode

• 10.1. Cloud
  • 10.1.1. Hybrid Cloud
  • 10.1.2. Private Cloud
  • 10.1.3. Public Cloud
• 10.2. On Premises
  • 10.2.1. Dedicated Servers
  • 10.2.2. Virtualization

11. Infection Surveillance Solution Market, by Application

• 11.1. Infection Control & HAI Surveillance
  • 11.1.1. Bloodstream Infections
  • 11.1.2. Surgical Site Infections
  • 11.1.3. Urinary Tract Infections
• 11.2. Outbreak Management
  • 11.2.1. Case Identification
  • 11.2.2. Contact Tracing
  • 11.2.3. Resource Allocation
• 11.3. Pathogen Genomics Analysis
• 11.4. Syndromic Surveillance

12. Infection Surveillance Solution Market, by End User

• 12.1. Diagnostic Labs
• 12.2. Hospitals
• 12.3. Public Health Agencies
• 12.4. Research Institutes

13. Infection Surveillance Solution Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Infection Surveillance Solution Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Infection Surveillance Solution Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Alcidion Group Limited
• 17.3. Ascom Holding AG
• 17.4. Baxter International Inc.
• 17.5. Becton, Dickinson and Company
• 17.6. bioMerieux SA
• 17.7. BioVigil Healthcare Systems, Inc.
• 17.8. Ecolab Inc.
• 17.9. Environmental Systems Research Institute, Inc.
• 17.10. Epic Systems Corporation
• 17.11. Getinge AB
• 17.12. GOJO Industries, Inc.
• 17.13. HealthConnex
• 17.14. InductiveHealth Informatics
• 17.15. Inovalon, Inc.
• 17.16. InterSystems Corporation
• 17.17. Juvare, LLC
• 17.18. Koninklijke Philips N.V.
• 17.19. Medical Information Technology, Inc.
• 17.20. Medtronic plc
• 17.21. Midmark Corporation
• 17.22. Nosotech
• 17.23. Oracle Corporation
• 17.24. Palantir Technologies Inc.
• 17.25. PointClickCare Technologies Inc.
• 17.26. RLDatix
• 17.27. SafeQual Health, L.P.
• 17.28. SAS Institute Inc.
• 17.29. STERIS plc
• 17.30. sterloCare
• 17.31. SwipeSense, Inc.
• 17.32. Vitalacy, Inc.
• 17.33. Wolters Kluwer N.V.
• 17.34. ZulaFly, Inc.